valsartan has been researched along with Myocardial Ischemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Du, F; Gao, Z; Hua, H; Jing, X; Li, S; Sun, G; Sun, J; Xiao, Y; Xu, W | 1 |
| Ioannou, A; Mandal, AKJ; Metaxa, S; Missouris, CG; Simon, S | 1 |
| Bonnet, D; Burch, M; Bush, C; Canter, C; Chen, F; Halnon, N; Kantor, P; Kochilas, L; Rossano, J; Shaddy, R; Zhao, Z | 1 |
| Balmforth, C; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shen, L; Shi, V; Simpson, J; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Amiya, E; Hirata, Y; Hosoya, Y; Kawarasaki, S; Nagai, R; Nakao, T; Omori, K; Ozeki, A; Tahara, Y; Takata, M; Watanabe, A; Watanabe, M; Watanabe, S; Yamada, N | 1 |
| Ahmed, A; Banach, M; Bielecka-Dabrowa, A; Misztal, M; Pietrucha, T; Rysz, J; Sakowicz, A; von Haehling, S | 1 |
| Dahlöf, B; Kanae, K; Mochizuki, S; Shimizu, M; Tajima, N; Taniguchi, I; Yoshida, S | 1 |
| Duarte, AI; Gonçalves, LM; Monteiro, P; Providência, LA | 1 |
| Ito, S; Kageyama, N; Nakaya, Y; Nomura, M; Watanabe, T | 1 |
| Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
4 trial(s) available for valsartan and Myocardial Ischemia
| Article | Year |
|---|---|
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Topics: Adolescent; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Infant, Newborn; Male; Myocardial Ischemia; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Alcoholic; Cardiomyopathy, Dilated; Cardiotoxicity; Cardiovascular Diseases; Cause of Death; Dangerous Behavior; Diabetic Cardiomyopathies; Drug Combinations; Enalapril; Female; Heart Failure; Heart Valve Diseases; Hospitalization; Humans; Hypertension; Infections; Male; Middle Aged; Mortality; Myocardial Ischemia; Peripartum Period; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Virus Diseases | 2019 |
Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autonomic Nervous System; Comorbidity; Drug Therapy, Combination; Endothelium, Vascular; Female; Fumarates; Heart Rate; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vasodilation | 2014 |
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Ischemia; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2004 |
7 other study(ies) available for valsartan and Myocardial Ischemia
| Article | Year |
|---|---|
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Topics: Administration, Oral; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Chronic Disease; Disease Models, Animal; Dogs; Drug Combinations; Heart Failure; Myocardial Ischemia; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Recovery of Function; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Systole; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Female; Genetic Markers; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Stroke Volume; Syndecan-4; Tetrazoles; Transforming Growth Factor beta1; Valsartan | 2016 |
Valsartan improves mitochondrial function in hearts submitted to acute ischemia.
Topics: Acute Disease; Adenosine Diphosphate; Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Heart; In Vitro Techniques; Intracellular Membranes; Membrane Potentials; Mitochondria, Heart; Myocardial Ischemia; Oxidative Phosphorylation; Oxygen Consumption; Rats; Rats, Wistar; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Relationship between adhesion molecules with hs-CRP and changes therein after ARB (Valsartan) administration in patients with obstructive sleep apnea syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; C-Reactive Protein; Case-Control Studies; Female; Humans; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Myocardial Ischemia; Sleep Apnea, Obstructive; Tetrazoles; Valine; Valsartan | 2006 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Coronary Vessels; Dogs; Enalaprilat; Female; Heart Rate; Hemodynamics; Male; Myocardial Ischemia; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Stroke Volume; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |